Likewise, there was high expression of miR-155 in estrogen receptor (ER)- and progesterone receptor (PR)-negative breast cancers and in triple-negative breast cancers (TNBCs), but there was no difference associated with human epidermal growth factor receptor 2 (HER2) status (Figure 1F–1G). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.